About morphedra
formerly known as OctapostAI · octapost.ai

Infrastructure for Scientific Visualization & Communication

morphedra (formerly OctapostAI) converts text — abstracts, results, key findings, published or not — into publication-ready visual outputs through a structured multimodal processing pipeline — built for researchers, journals, NGOs, industries, and scientific institutions worldwide.

The Company

morphedra (formerly OctapostAI) is a product of AN-MAYS (SMC-PRIVATE) LIMITED, a technology company registered under the Securities and Exchange Commission of Pakistan (SECP).

We build tools that eliminate friction in scientific communication — giving researchers the ability to produce publication-grade visuals with the same rigor they bring to their science.

Our platform is publicly available globally at morphedra.com, serving researchers and institutions across 50+ countries.

Legal Name

AN-MAYS (SMC-PRIVATE) LIMITED

Registration

SECP (Pakistan)

Business Model

Digital-native SaaS

Product

morphedra.com (formerly octapost.ai)

Users

350+ researchers · 50+ countries

Sustainability & Business Model

Freemium SaaS

Supporting the global scientific community with a free-forever tier for individual researcher accessibility.

Institutional B2B

Enterprise-grade subscriptions for research labs and universities requiring high-resolution batch processing.

API Infrastructure

Infrastructure-as-a-Service for academic journals to automate graphical abstract generation at the DOI level.

The Platform

A structured pipeline that ingests research inputs and generates multimodal scientific outputs.

📝

Text Input

Abstract, results, or key findings

🧠

Multimodal Reasoning

Multimodal scientific parsing

🎨

Visual Generation

2D diagrams · 3D cover art

🎬

Video Abstracts

Powered by Google Veo 2

Technology Stack

Multimodal Reasoning PipelineCrossref DOI IngestionOpenAlex APIPubMed Integration2D & 3D GenerationScientific Video GenerationCloud Infrastructure

Team

AN

Akhtar Nadhman, PhD

Founder & CEO · morphedra

AN-MAYS (SMC-PRIVATE) LIMITED

Visiting Researcher · Harvard Medical SchoolNanobiotechnology Specialist75+ Peer-reviewed publicationsTop 2% Most-Cited · Stanford-Elsevier 2022

Visiting Researcher

Harvard Medical School

Nanobiotechnology Specialist

75+ peer-reviewed publications

Top 2% Most-Cited Scientist

Stanford-Elsevier Global Ranking (2022)

Based in Pakistan

Building globally

"I built the platform I wish existed during my research career — where generating publication-quality visuals takes seconds, not weeks. Great science deserves to be seen."

75+

Publications

Top 2%

Cited Scientist

250+

Researchers Served

50+

Countries

Our Mission

morphedra exists to eliminate friction in scientific communication. We are building infrastructure that lets researchers focus on discovery — not design software.

Great science goes unread because researchers lack efficient tools for visual clarity. We are changing that — one figure at a time.

Start Free Today

No credit card required · 2 free illustrations/month forever